A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

NCT05489289 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

570

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: AK104
BIOLOGICAL: placebo

Sponsor

Akeso